Ta Hsung Tung

Array ( [id] => 13982587 [patent_doc_number] => 20190060451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => ANTIGEN BINDING PROTEINS THAT BIND PD-L1 [patent_app_type] => utility [patent_app_number] => 16/111995 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072385 [patent_doc_number] => 20190085080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => B7-H4 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/111064 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16198649 [patent_doc_number] => 10723799 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Anti-PD-L1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/100065 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23985 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944721 [patent_doc_number] => 10208119 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Anti-PD-L1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/100019 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23924 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808222 [patent_doc_number] => 20210130775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR OR ENGINEERED TCR AND COMPRISING A NUCLEOTIDE SEQUENCE WHICH IS SELECTIVELY EXPRESSED [patent_app_type] => utility [patent_app_number] => 16/635740 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18965260 [patent_doc_number] => 11899017 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Predictive peripheral blood biomarker for checkpoint inhibitors [patent_app_type] => utility [patent_app_number] => 16/634833 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 25 [patent_no_of_words] => 22772 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929135 [patent_doc_number] => 20190048083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => REGULATORY T CELL MEDIATOR PROTEINS AND USES THEROF [patent_app_type] => utility [patent_app_number] => 16/046660 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963193 [patent_doc_number] => 20200165348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => CD123-BINDING CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/632086 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339462 [patent_doc_number] => 12049643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Methods and compositions for modulating cytotoxic lymphocyte activity [patent_app_type] => utility [patent_app_number] => 16/630887 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 134 [patent_no_of_words] => 109796 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575529 [patent_doc_number] => 11732043 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Antibodies that modulate a biological activity expressed by a cell [patent_app_type] => utility [patent_app_number] => 16/628939 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 40 [patent_no_of_words] => 26719 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14390889 [patent_doc_number] => 10308714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/024340 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39903 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422603 [patent_doc_number] => 10316091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/024333 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39863 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618807 [patent_doc_number] => 20180360955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES [patent_app_type] => utility [patent_app_number] => 16/016770 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16275604 [patent_doc_number] => 10758611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Vector co-expressing vaccine and costimulatory molecules [patent_app_type] => utility [patent_app_number] => 16/016771 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 49 [patent_no_of_words] => 24853 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13606985 [patent_doc_number] => 20180355041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => Antibodies to ICOS [patent_app_type] => utility [patent_app_number] => 16/012867 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16012867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251239 [patent_doc_number] => 10138299 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/006473 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39848 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461743 [patent_doc_number] => 20180282414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING [patent_app_type] => utility [patent_app_number] => 16/006493 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422601 [patent_doc_number] => 10316090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/006365 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39859 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733233 [patent_doc_number] => 20180371084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 15/995584 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227196 [patent_doc_number] => 12415839 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => IgE epitope-like peptides and uses thereof [patent_app_type] => utility [patent_app_number] => 17/058367 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5089 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 301 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058367 [rel_patent_id] =>[rel_patent_doc_number] =>)